Citizens JMP Analyst Reiterates Hold Rating on Instil Bio

Citizens JMP analyst Reni Benjamin reiterated a Hold rating on Instil Bio, with shares opening at $28.65. Benjamin has an average return of -12.6% and a 34.28% success rate on recommended stocks. The overall analyst consensus rating for Instil Bio is Moderate Buy with a $125.00 average price target. Instil Bio has a market cap of $190.7M and a P/E ratio of -2.19.

Instil Bio, Inc. (NASDAQ: TIL), a biotechnology company focused on developing innovative therapies for cancer treatment, has reported its second-quarter 2025 financial results. The company reported a non-GAAP earnings per share (EPS) of -$3.24, as of June 30, 2025 [1]. This marks a significant increase from the previous year's EPS of $2.29.

The company's financial highlights for the quarter include a net loss of $21.4 million, up from $14.9 million in the prior year. Total operating expenses increased to $23.4 million, reflecting higher research and development costs and in-process research and development expenses. Interest income decreased to $1.0 million, while interest expense fell to $1.6 million, indicating reduced debt-related costs [2].

Instil Bio is advancing its lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting PD-L1 and VEGF in solid tumor cancers. The company is also exploring additional therapeutic candidates in diseases with significant unmet medical need. In August 2024, Axion Bio, a subsidiary of Instil Bio, in-licensed bispecific antibodies from ImmuneOnco Biopharmaceuticals, including AXN-2510/IMM2510 and AXN-27M/IMM27M [2].

Citizens JMP analyst Reni Benjamin reiterated a Hold rating on Instil Bio, with shares opening at $28.65. Benjamin has an average return of -12.6% and a 34.28% success rate on recommended stocks. The overall analyst consensus rating for Instil Bio is Moderate Buy with a $125.00 average price target. Instil Bio has a market cap of $190.7 million and a P/E ratio of -2.19 [3].

Instil Bio expects to continue incurring net losses as it invests in the development of AXN-2510/IMM2510 and explores additional in-licensing or acquisition opportunities. The company anticipates that its existing cash resources will fund operations beyond 2026, with potential extension from the sale of the Tarzana facility [2].

References:
[1] https://seekingalpha.com/news/4484597-instil-bio-non-gaap-eps-of-3_24
[2] https://www.tradingview.com/news/tradingview:7c78fb850e46b:0-instil-bio-inc-sec-10-q-report/
[3] https://www.tradingview.com/news/tradingview:7c78fb850e46b:0-instil-bio-inc-sec-10-q-report/